Diniz M J, Dias Francisco F, Tavares M L, Leal I
Serviço de Imuno-Hemoterapia, Hospital de S. José, Lisboa.
Acta Med Port. 1992 Apr;5(4):178-80.
Factor VIII inhibitors arise in 5% to 15% of patients with hemophilia A in response to infusion to factor VIII concentrates and make the treatment of bleeding episodes extremely difficult. Various therapeutic approaches have been tried the decision depending on the type of haemorrhage, the antibody's titre and whether the patient has a low or high response. We report the clinical experience in 13 hemophiliacs with inhibitors to factor VIII. Prothrombin complex concentrates were administered with favorable effects in the most common haemorrhagic episodes, in the majority of patients. In two patients activated prothrombin complex concentrates were administered and in one case plasma exchange was made before high doses of factor VIII. These therapeutic approaches proved to be very effective in the control of hemostasis.
8%的甲型血友病患者在输注凝血因子VIII浓缩物后会产生VIII因子抑制剂，这使得出血发作的治疗极为困难。针对不同类型的出血、抗体滴度以及患者的低反应或高反应情况，人们尝试了各种治疗方法。我们报告了13例患有VIII因子抑制剂的血友病患者的临床经验。在大多数患者中，给予凝血酶原复合物浓缩剂对最常见的出血发作有良好效果。有2例患者给予了活化凝血酶原复合物浓缩剂，1例患者在大剂量输注VIII因子前进行了血浆置换。这些治疗方法在控制止血方面被证明非常有效。
